S-1/A: Qualigen Therapeutics Eyes $4 Million Raise Through Stock and Warrant Offering

Qualigen Therapeutics aims to raise up to $4 million through a public offering of common stock and pre-funded warrants to advance its clinical programs and for general corporate purposes.

Summary

• Qualigen Therapeutics is undertaking a public offering to raise up to $4 million through the sale of common stock and pre-funded warrants.
• The offering includes shares of common stock and pre-funded warrants, with each pre-funded warrant exercisable for one share of common stock at a nominal exercise price of $0.001.
• The pre-funded warrants are offered as an alternative for investors who might exceed beneficial ownership limitations.
• Univest Securities, LLC is acting as the exclusive placement agent for the offering.
• The company intends to use the net proceeds for clinical trial advancement, preclinical studies, debt repayment, potential expansion of its relationship with Marizyme, Inc., and possible future acquisitions.
• The offering is expected to close around August [*], 2024, but may terminate earlier if fully subscribed or if the company decides to terminate it.
• The company's lead program, QN-302, is currently undergoing a Phase 1a clinical trial, and the Pan-RAS program is in the preclinical stage.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is raising capital, which is generally positive, there are also risks and uncertainties associated with the offering, such as potential dilution and the company's financial condition.

Positives

• The company's lead drug candidate, QN-302, has received Orphan Drug Designation from the FDA for pancreatic cancer, providing potential benefits such as marketing exclusivity and tax credits.
• The company has a co-development agreement with Marizyme, Inc. related to the DuraGraft vascular conduit solution, which could provide a revenue stream.
• The company has an exclusive license agreement with the University of Louisville Research Foundation (UofL) for the intellectual property covering the RAS family of pan-RAS inhibitor small molecule drug candidates.

Negatives

• The company's independent registered public accounting firm included an explanatory paragraph in its report on the company's financial statements for the year ended December 31, 2023 with respect to uncertainty about its ability to continue as a going concern.
• The company has a working capital deficiency, stockholders deficit, and recurring losses from operations.
• The company may sell fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds received by the company.
• There is no established public trading market for the pre-funded warrants being offered in this offering.
• The company has been in noncompliance with Nasdaq's continued listing rules in the past and may be delisted if it fails to satisfy the continued listing requirements of Nasdaq.
• The company has discontinued its efforts as to the QN-247, QN-165 and STARS programs.

Risks

• The price of the company's common stock may be highly volatile.
• The company's failure to develop or maintain effective internal controls over financial reporting could harm its operating results.
• The company's failure to meet the continued listing requirements of Nasdaq could result in a delisting of its common stock.
• Investors will experience immediate and substantial dilution as a result of this offering.
• The company's management will have broad discretion over the use of the net proceeds from this offering.
• This is a best efforts offering; no minimum amount of securities is required to be sold, and the company may not raise the amount of capital it believes is required for its business.
• There is no public market for the pre-funded warrants being offered in this offering.
• There is no assurance that the company and Marizyme will agree to any expanded relationship, or that any expanded relationship which is agreed to would be favorable to the company.

Future Outlook

The company intends to use the net proceeds from the sale of the securities offered by us pursuant to this prospectus for our operations and for other general corporate purposes, including, but not limited to, advancement of our clinical trial and preclinical studies, general working capital, payment on an accelerated basis of the $1,100,000 principal amount of the 2024 Chen Debenture and the $550,000 principal amount of the 2024 Alpha Debenture (unless Alpha and Chen agree to waive in part or in whole the closing of this offering as an event which accelerates the maturity of the 2024 Chen Debenture and of the 2024 Alpha Debenture), required payment of 20% of the proceeds from this offering pursuant to the terms of a $2,000,000 Senior Note issued in July 2024, possible expansion of our relationship with Marizyme, Inc. under the Co-Development Agreement, and possible future acquisitions.

Industry Context

This announcement reflects a common strategy for small, early-stage biotech companies to raise capital to fund ongoing research and development activities, particularly clinical trials. The use of pre-funded warrants is a mechanism to accommodate investors with ownership limitations, which is not uncommon in the micro-cap space.

Comparison to Industry Standards

• Comparable companies in the early-clinical-stage therapeutics space often rely on public offerings to fund their research and development activities.
• The terms of the offering, including the placement agent fee and the use of pre-funded warrants, are generally consistent with industry standards for similar-sized companies.
• The company's lead drug candidate, QN-302, has received Orphan Drug Designation from the FDA for pancreatic cancer, which is a common milestone for companies developing treatments for rare diseases.

Management Changes

Stakeholder Impact

• Shareholders may experience dilution as a result of the offering.
• Employees may benefit from the company's ability to fund ongoing research and development activities.
• Customers may benefit from the development of new treatments for cancer.
• Creditors may be impacted by the company's use of proceeds to repay debt.

Next Steps

• The company will proceed with the public offering, subject to market conditions and regulatory approvals.
• The company will use the net proceeds for clinical trial advancement, preclinical studies, debt repayment, potential expansion of its relationship with Marizyme, Inc., and possible future acquisitions.
• The company will continue to develop its QN-302 and Pan-RAS programs.

Key Dates

Keywords

Qualigen Therapeutics, public offering, common stock, pre-funded warrants, QN-302, Pan-RAS, clinical trials, FDA, Orphan Drug Designation, Marizyme, DuraGraft, Univest Securities